William Sietsema - Lisata Therapeutics Vice Affairs
| LSTA Stock | USD 2.82 0.02 0.70% |
Executive
William Sietsema is Vice Affairs of Lisata Therapeutics
| Age | 68 |
| Address | 110 Allen Road, Basking Ridge, NJ, United States, 07920 |
| Phone | 908 842 0100 |
| Web | https://www.lisata.com |
Lisata Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2872) % which means that it has lost $0.2872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4403) %, meaning that it created substantial loss on money invested by shareholders. Lisata Therapeutics' management efficiency ratios could be used to measure how well Lisata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.56. At present, Lisata Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 1.5 M, whereas Total Assets are forecasted to decline to about 43.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Philip JD | Monte Rosa Therapeutics | 45 | |
| MS MD | Candel Therapeutics | 55 | |
| Anthony Price | Bio Path Holdings | N/A | |
| Marianne Lambertson | Imunon Inc | N/A | |
| Gary Gentges | Kineta Inc | N/A | |
| Johannes MD | Lixte Biotechnology Holdings | 68 | |
| Jacques Bouchy | Kineta Inc | 55 | |
| Khursheed MBA | Imunon Inc | 64 | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Samuel MD | Tempest Therapeutics | 58 | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| MD FACP | Moleculin Biotech | 72 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Sebastien MD | Imunon Inc | 52 | |
| David Gaiero | Imunon Inc | 46 | |
| Daron Evans | Rezolute | 50 | |
| David JD | Pulmatrix | 66 | |
| ScD MD | Moleculin Biotech | 72 | |
| Michael Deperro | Rezolute | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 |
Lisata Therapeutics Leadership Team
Elected by the shareholders, the Lisata Therapeutics' board of directors comprises two types of representatives: Lisata Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lisata. The board's role is to monitor Lisata Therapeutics' management team and ensure that shareholders' interests are well served. Lisata Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lisata Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kristen MD, Executive Officer | ||
| Gail Holler, Vice Resources | ||
| James Nisco, Treasurer, Finance | ||
| Tariq Imam, Vice Counsel | ||
| Ian MBA, Inc NeoStem | ||
| Gregory Berkin, Chief Officer | ||
| John Menditto, Vice Communications | ||
| Eric Powers, Director Marketing | ||
| William Sietsema, Vice Affairs | ||
| David MBA, Chief Pres | ||
| BSc B, CEO President |
Lisata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lisata Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (11.83 M) | ||||
| Shares Outstanding | 8.39 M | ||||
| Shares Owned By Insiders | 19.12 % | ||||
| Shares Owned By Institutions | 9.07 % | ||||
| Number Of Shares Shorted | 17.06 K | ||||
| Price To Book | 0.71 X | ||||
| EBITDA | (25.52 M) | ||||
| Net Income | (20.84 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Return On Assets (0.29) | Return On Equity (0.44) |
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.